Evidence map›Paper›PMID 42302265›Full record

ArticleJMIR research protocols2026

Deep-Learning Solution Providing Molecular Marker Subtyping of Breast Cancer Whole Slide Images: Protocol for a UK Clinical Service Evaluation Study.

Elizabeth Walsh, Dildar Rathore, André Geraldes, Salim Arslan, Andrew M Hanby, Rebecca Millican-Slater, Michael Drummond, Olorunda Rotimi, Narender Kumar, Pahini Pandya and 1 more

Abstract read
In one paragraph

Article in JMIR research protocols, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Elizabeth Walsh *Leeds Institute of Medical Research, Faculty of Medicine, University of Leeds, Leeds, United Kingdom.ORCID 0009-0003-4211-4516
Dildar RathoreHistopathology Department, St James's University Hospital, Leeds, United Kingdom.ORCID 0000-0002-2316-2999
André GeraldesPanakeia Technologies Ltd, Cambridge, United Kingdom.ORCID 0000-0002-5113-6587
Salim ArslanPanakeia Technologies Ltd, Cambridge, United Kingdom.ORCID 0000-0002-4329-0947
Andrew M HanbyLeeds Institute of Medical Research, Faculty of Medicine, University of Leeds, Leeds, United Kingdom.ORCID 0000-0001-7966-1570
Rebecca Millican-SlaterHistopathology Department, St James's University Hospital, Leeds, United Kingdom.ORCID 0000-0001-6280-4598
Michael DrummondCentre for Health Economics, University of York, York, United Kingdom.ORCID 0000-0002-6126-0944
Olorunda RotimiHistopathology Department, St James's University Hospital, Leeds, United Kingdom.ORCID 0000-0003-0890-0399
Narender KumarPanakeia Technologies Ltd, Cambridge, United Kingdom.ORCID 0000-0003-2089-9626
Pahini PandyaPanakeia Technologies Ltd, Cambridge, United Kingdom.ORCID 0000-0003-0890-0399
Nicolas M OrsiLeeds Institute of Medical Research, Faculty of Medicine, University of Leeds, Leeds, United Kingdom.ORCID 0000-0003-0890-0399

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs the histopathology workforce continues to struggle and service demand continues to increase, it has become prudent to consider viable avenues to try to alleviate diagnostic workload burden. One such avenue is computer-based technologies (CBTs). Breast cancer (BC) is the most common malignant neoplasm in the United Kingdom and requires additional testing for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2) status at the time of histological diagnosis. This makes BC diagnostics a promising candidate for the application of an efficient CBT. However, for clinical acceptance, these technologies must prove that they work within a real-life diagnostic environment.

objectiveWe present a study protocol for a prospective clinical service evaluation aimed to validate a UK Conformity Assessed-marked CBT's ability to provide ER, PR, and HER2 results for invasive BCs from scanned hematoxylin and eosin-stained whole slide images.

methodsThis protocol has been designed to use and mimic a preexisting digital pathology workflow within a National Health Service tertiary referral cancer center without disrupting normal patient care. Eligible cases are identified prospectively through the laboratory information management system, and their whole slide images are extracted from the clinical digital workflow. After verification of national data opt-out status and the exclusion of appropriate cases (N=400 analyzable cases), these cases are analyzed on a dedicated computer in parallel to the existing clinical workflow by a UK Conformity Assessed-marked deep learning-based CBT in a separate environment, providing results for ER, PR, and HER2 status. These results are compared to the ER, PR, and HER2 status reported on the corresponding pathology report. To evaluate the CBT's performance, a range of accepted concordance measures will be applied, including specificity, sensitivity, false-positive rate, false-negative rate, positive predictive value, and negative predictive value. Moreover, time stamps representing the duration of image analysis will also be collected.

resultsThis study started in April 2025. There are no results to present, as this paper focuses on study design, and results have yet to be generated. As of March 2026, overall, 366 potentially analyzable cases have been collected. The anticipated end date of the study is May 2026 (400-case target). Results will be presented in a separate publication.

conclusionsThis design assesses a CBT within a clinical environment while effectively eliminating any unwanted effects on patient care. This type of service evaluation provides a useful step to establish confidence in a CBT before trialing its effect on patient care. It also offers the opportunity to support interventional randomized controlled trials, health economic evaluations, and usability studies. This protocol will hopefully prove useful to others who wish to conduct a similar service evaluation at their own institution. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/76785.

Indexed as

Biomarkers, TumorBreast NeoplasmsDeep LearningErb-b2 Receptor Tyrosine KinasesFemaleHumansProspective StudiesReceptors, EstrogenReceptors, ProgesteroneUnited KingdomBiomarkers, TumorERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneAIartificial intelligencebreast cancerdeep learningdigital pathologyprotocolservice evaluation

Identifiers

PMID42302265
PMCPMC13320011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.